Tasly Group Halts Trading After Adverse Report On Its Cardiotonic Pill
An academic fingered for falsifying his research paper has turned the table on the accuser after Zhejiang University found the real author to be a protégé. Li Lianda, the implicated academic, claimed the allegation was made by an advisor of Tasly Group after Li announced his research on the severe side effects caused by the firm's Cardiotonic Pill. The company asked him not to publish the results but he went ahead, thus he suspected the false paper "exposé" was linked to the incident. Upon media reporting of Li's statement, Tasly Group's share dropped 3.8 percent, leading to an urgent halt in trading. The firm issued a statement that the advisor's accusation was made in his personal capacity and denied any association. It emphasized that the drug has received China State FDA approval after thousands of clinical trials. (Click here for more - Chinese Language)
More from Archive
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
More from Scrip
Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.
Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.
Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.